Topical transdermal method for delivering nutrients through the skin for expedited wound healing

Abstract

The present invention proposes a cosmetic or pharmaceutical preparation that comprises a mixture of nutritional related co-factors synergistically combined and applied as a topical/transdermal surfactant. Said surfactant formula invokes a precise ordered and sequential synchrony within the treated area initiating the bodies' own natural biological and healing circadia. Said surfactant formula has the ability to regulate an inflammation response and infuse required nutrients for cellular repair at the treated area. The specific ingredients serve as a co-synergist for a clearly defined series of cascading biochemical loops that substantiate the use of each individual ingredient. The concert of regulation of an inflammation response coupled with infused nutritional co-factors and cascading biochemical loops yields a modulation of both chronic and acute inflammation or repair of injured tissue and joints as a result of injury, stress or disease.

1 . A cosmetic or pharmaceutical composition comprising between 0.001% and 2% methyl nicotinate by weight and between 0.01% and 10% by weight of vitamins, minerals and amino acids, selected from a group consisting of but not limited to: alpha lipoic acid, aminoacetic acid, 3-aminopropionic acid (beta alanine), 1-histidine, hypoxanthine riboside, copper, tocopherols, pyridoxal-5-phosphate, ascorbyl palmitate, niacinamide, histamine, taurine, nicotinic acid, Vitamin C. 
     
     
         2 . A composition of  claim 1  comprising a mixture in liquid , gel or cream format containing between, 1% and 50%, by weight in said preparation from a group consisting of medium chain triglycerides, phophatidyl choline, glycerol, polysorbate 80 or 20, propylene glycol, oleic acid and alcohol. 
     
     
         3 . Composition of  claim 2  wherein said liquid is further comprised of water. 
     
     
         4 . A composition of  claim 1  wherein the said compositions is used as topical/transdermal cosmetic preparation comprising, in a liquid, gel or cream format comprising between 0.001% and 2% methyl nicotinate by weight and between 0.01% and 10% by weight of vitamins, minerals and amino acids, selected from a group consisting of but not limited to: alpha lipoic acid, aminoacetic acid, 3-aminopropionic acid (beta alanine), 1-histidine, hypoxanthine riboside, copper, tocopherols, pyridoxal-5-phosphate, ascorbyl palmitate, niacinamide, histamine, taurine, nicotinic acid, Vitamin C. 
     
     
         5 . Composition of  claim 4  further comprising between 1% and 50%, by weight in said preparation from a group consisting of but not limited to: medium chain triglycerides, phophatidyl choline, glycerol, polysorbate 80 or 20, propylene glycol, oleic acid and alcohol. 
     
     
         6 . Composition of  claim 4  wherein said topical/transdermal pharmaceutical preparationcomprising between 0.001% and 2% methyl nicotinate by weight and between 0.01% and 10% by weight of vitamins, minerals and amino acids, selected from a group consisting of but not limited to: alpha lipoic acid, aminoacetic acid, 3-aminopropionic acid (beta alanine), 1-histidine, hypoxanthine riboside, copper, tocopherols, pyridoxal-5-phosphate, ascorbyl palmitate, niacinamide, histamine, taurine, nicotinic acid, Vitamin C. 
     
     
         7 . Composition of  claim 6  further comprising between 1% and 50%, by weight in said preparation from a group consisting of but not limited to: medium chain triglycerides, phosphatidyl choline, glycerol, polysorbate 80 or 20, propylene glycol and alcohol. 
     
     
         8 . A method of modulating inflammation and apoptosis through topical/transdermal delivery of nutrients listed in  claim 6  and  claim 7 . 
     
     
         9 . The method according to  claim 8 , wherein said modulator affects selective Cytokine receptors composed of two or more polypeptide chains. 
     
     
         10 . The method according to  claim 8 , wherein said modulator comprises Mitogen-activated protein kinase kinase, (MEKK). 
     
     
         11 . The method according to  claim 8 , wherein said modulator in humans is encoded by the MAP3K1 gene. 
     
     
         12 . The method according to  claim 11 , wherein said molecule is the MAP3K gene. 
     
     
         13 . The method according to  claim 8 , wherein said modulator is derived from and encoded to the MEK kinase. 
     
     
         14 . A method according to  claim 8 , of preventing and reducing inflammation and cellular insult by the creation of a chimera in the form of an autocoid, thereby creating a false analogue truncating the pro-inflammatory cascade. 
     
     
         15 . This method according to  claim 8 , augments the healing and cellular repair due to increased blood flow through the innate healing response with an effective topical dose of the modulator of integrin-linked kinase. 
     
     
         16 . A method for the instant and spontaneous delivery of nutrients to injured tissue by the intervention and delivery of a methylated form of nicotinic acid. 
     
     
         17 . The method, according to  claim 16 , wherein said molecule enables, facilitates and expedites enhanced and spontaneous transfer across the plasma membrane. 
     
     
         18 . The method, according to  claim 16 , wherein the delivery mechanism comprises a small organic molecule with direct influence on the cannabinoid receptor, CB1. 
     
     
         19 . CB 1  cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death. This composition according to  claim 8 , creates false analogues of the PGE 2 series, mimicking a temporary and site-specific inflammatory marker directly initiating and recruiting CB1. 
     
     
         20 . Herein, is a compound pursuant to  claim 18 , that facilitates the antihyperalgesic effect of peripheral CB1 agonists through the creation of an autocoid chimera creating a temporary inflammatory response. 
     
     
         21 . This compound according to  claim 8 , induces the enabling of the CB1 cannabinoid receptor. 
     
     
         22 . The method of  claim 18 , wherein both cellular repair and tissue healing and repair are accelerated by directly increasing intra-mitochondrial energy stores. 
     
     
         23 . The method of inducing Ribosome switch activation by the introduction of (said) various compounds, listed in  claim 1  and  claim 2 , for gene repair and/or gene expression and/or gene silencing. 
     
     
         24 . The method according to  claim 23 , where the compound contains thiamine. 
     
     
         25 . The method according to  claim 23 , where the compound is a Methyl donor group. 
     
     
         26 . The method according to  claim 23 , where the compound contains glycine. 
     
     
         27 . The method according to  claim 23 , where the compound contains B-alanine. 
     
     
         28 . The method according to  claim 23 , where the compound contains Pyridoxal-5-Phospate. 
     
     
         29 . The method according to  claim 23 , where the compound contains Inosine. 
     
     
         30 . The method of inducing Aquaporine (AQP0) channels opening by the introduction and or recruitment of specific amino acids. 
     
     
         31 . The method according to  claim 23 , where the compound contains L-Histidine 
     
     
         32 . The method according to  claim 23 , where the compound contains histamine. 
     
     
         33 . The method according to  claim 14 , where a false analog is used to recruit free Histidine in tissue to induce Aquaporine channels (AQP0) to open,  claim 30 . 
     
     
         34 . The method according to  claim 19 , where Prostaglandin of the 2 series (PGE2) activation is used to recruit free Histidine in tissue to induce Aquaporine channels (AQP0) to open,  claim 30 . 
     
     
         35 . A composition according to  claim 1  and  claim 2 , for the instant and spontaneous delivery of specific triglycerides into the mitochondria for Fatty acid degradation for energy release. 
     
     
         36 . The composition according to  claim 35 , where the compound contains varying Medium chain triglycerides (MCT) from 6 to 12 carbons. 
     
     
         37 . The use of composition according to  claim 1  and  claim 2 , to induce the production of collagen in human tissue.